Hyperbaric medicine

Hyperbaric medicine is a medical treatment in which an increase in barometric pressure over ambient pressure is employed increasing the partial pressures of all gases present in the compressed air. The immediate effects include reducing the size of gas embolisms and raising the partial pressures of all gases present according to Henry's law. Currently, there are two types of hyperbaric medicine depending on the gases compressed, hyperbaric air and hyperbaric oxygen.

Hyperbaric air (HBA), consists of compressed room air (79% nitrogen, 21% oxygen, and minor gases) and is FDA-approved for acute mountain sickness. The hyperbaric air environment is created by placing the patient in a portable hyperbaric air chamber and inflating that chamber up to 7.35 psi gauge (1.5 atmospheres absolute) using a foot-operated or electric air pump. Although the mechanisms of hyperbaric air are poorly understood it is thought that it relieves hypoxemia caused by the decreased partial pressure of oxygen resulting from high altitude by increasing the partial pressure of air (including oxygen and nitrogen) simulating a descent in altitude.

Hyperbaric oxygen therapy (HBOT), the medical use of greater than 99% oxygen at an ambient pressure higher than atmospheric pressure, and therapeutic recompression for decompression illness, intended to reduce the injurious effects of systemic gas bubbles by physically reducing their size and providing improved conditions for elimination of bubbles and excess dissolved gas.

The equipment required for hyperbaric oxygen treatment consists of a Pressure vessel for human occupancy, which may be of rigid or flexible construction, and a means of a controlled atmosphere. Operation is performed to a predetermined schedule by trained personnel who monitor the patient and may adjust the schedule as required. HBOT found early use in the treatment of decompression sickness, and has also shown great effectiveness in treating conditions such as gas gangrene and carbon monoxide poisoning. More recent research has examined the possibility that it may also have value for other conditions such as cerebral palsy and multiple sclerosis, but no significant evidence has been found.

A Pressure vessel for human occupancy (PVHO) is an enclosure that is intended to be occupied by one or more persons at a pressure which differs from ambient by at least 2 psi. All chambers made for hyperbaric medicine fall under the jurisdiction of the Federal Food and Drug Agency (FDA). The FDA requires hyperbaric chambers to comply with the American Society of Mechanical Engineers PVHO Codes and the National Fire Protection Association Standard 99, Health Care Facilities Code.

Hyperbaric medicine poses some inherent hazards that are mitigated by FDA-compliant equipment and trained personnel. Serious injury can occur at pressures as low as 2 psig (13.8 kPa) if a person in the PVHO is rapidly decompressed. If oxygen is used in the hyperbaric therapy, this can increase the fire hazard. This is why the FDA requires hyperbaric chambers to meet ASME PVHO and NFPA 99 standards. All chambers that meet FDA standards must have an ASME data plate, and people seeking hyperbaric treatment should check to ensure the equipment and facilities are to proper standards.

Therapeutic recompression is usually also provided in a hyperbaric chamber. It is the definitive treatment for decompression sickness and may also be used to treat arterial gas embolism caused by pulmonary barotrauma of ascent. In emergencies divers may sometimes be treated by in-water recompression (when a chamber is not available) if suitable diving equipment (to reasonably secure the airway) is available.

A number of hyperbaric treatment schedules have been published over the years for both therapeutic recompression and hyperbaric oxygen therapy for other conditions.

Scope
Hyperbaric medicine includes hyperbaric oxygen treatment, which is the medical use of oxygen at greater than atmospheric pressure to increase the availability of oxygen in the body; and therapeutic recompression, which involves increasing the ambient pressure on a person, usually a diver, to treat decompression sickness or an air embolism by eliminating bubbles that have formed within the body.

Medical uses
In the United States the Undersea and Hyperbaric Medical Society, known as UHMS, lists approvals for reimbursement for certain diagnoses in hospitals and clinics. The following indications have approved (for reimbursement) uses of hyperbaric oxygen therapy as defined by the UHMS Hyperbaric Oxygen Therapy Committee:
 * Air or gas embolism;
 * Carbon monoxide poisoning;
 * Carbon monoxide poisoning complicated by cyanide poisoning;
 * Central retinal artery occlusion;
 * Clostridal myositis and myonecrosis (gas gangrene);
 * Crush injury, compartment syndrome, and other acute traumatic ischemias;
 * Decompression sickness;
 * Enhancement of healing in selected problem wounds;
 * Diabetically derived illness, such as short-term relief of diabetic foot,  diabetic retinopathy,  diabetic nephropathy;
 * Exceptional blood loss (anemia);
 * Idiopathic sudden sensorineural hearing loss;
 * Intracranial abscess;
 * Mucormycosis, especially rhinocerebral disease in the setting of diabetes mellitus;
 * Necrotizing soft tissue infections (necrotizing fasciitis);
 * Osteomyelitis (refractory);
 * Delayed radiation injury (soft tissue and bony necrosis);
 * Skin grafts and flaps (compromised);
 * Thermal burns.

There is no reliable evidence to support its use in autism, cancer, diabetes, HIV/AIDS, Alzheimer's disease, asthma, Bell's palsy, cerebral palsy, depression, heart disease, migraines, multiple sclerosis, Parkinson's disease, spinal cord injury, sports injuries, or stroke. Furthermore, there is evidence that potential side effects of hyperbaric medicine pose an unjustified risk in such cases. A Cochrane review published in 2016 reviewed a small set of clinical trials attempting to treat autism spectrum disorders with hyperbaric oxygen therapy. They noted a small sample size and large "confidence intervals" did not provide much evidence. No links between improvements in social abilities or cognitive function were noted. There are also ethical issues with further trials, as the eardrum can be damaged during hyperbaric therapy. Despite the lack of evidence, in 2015, the number of people utilizing this therapy has continued to rise.

There is also insufficient evidence to support its use in acute traumatic or surgical wounds.

Hearing issues
There is limited evidence that hyperbaric oxygen therapy improves hearing in patients with sudden sensorineural hearing loss who present within two weeks of hearing loss. There is some indication that HBOT might improve tinnitus presenting in the same time frame.

Chronic ulcers
HBOT in diabetic foot ulcers increased the rate of early ulcer healing but does not appear to provide any benefit in wound healing at long-term follow-up. In particular, there was no difference in major amputation rate. For venous, arterial and pressure ulcers, no evidence was apparent that HBOT provides a long-term improvement over standard treatment.

Radiation injury
There is some evidence that HBOT is effective for late radiation tissue injury of bone and soft tissues of the head and neck. Some people with radiation injuries of the head, neck or bowel show an improvement in quality of life. Importantly, no such effect has been found in neurological tissues. The use of HBOT may be justified to selected patients and tissues, but further research is required to establish the best people to treat and timing of any HBO therapy.

Neuro-rehabilitation
As of 2012, there was no sufficient evidence to support using hyperbaric oxygen therapy to treat people who have traumatic brain injuries. In acute stroke, HBOT does not show benefit. Small clinical trials, however, have shown benefits from HBOT for stroke survivors between 6 months to 3 years after the acute phase.

HBOT in multiple sclerosis has not shown benefit and routine use is not recommended.

A 2007 review of HBOT in cerebral palsy found no difference compared to the control group. Neuropsychological tests also showed no difference between HBOT and room air and based on caregiver report, those who received room air had significantly better mobility and social functioning. Children receiving HBOT were reported to experience seizures and the need for tympanostomy tubes to equalize ear pressure, though the incidence was not clear.

Cancer
In alternative medicine, hyperbaric medicine has been promoted as a treatment for cancer. However, a 2011 study by the American Cancer Society reported no evidence it is effective for this purpose. A 2012 review article in the journal, Targeted Oncology, reports that "there is no evidence indicating that HBO neither acts as a stimulator of tumor growth nor as an enhancer of recurrence. On the other hand, there is evidence that implies that HBO might have tumor-inhibitory effects in certain cancer subtypes, and we thus strongly believe that we need to expand our knowledge on the effect and the mechanisms behind tumor oxygenation."

Migraines
Low-quality evidence suggests that hyperbaric oxygen therapy may reduce the pain associated with an acute migraine headache in some cases. It is not known which people would benefit from this treatment, and there is no evidence that hyperbaric medicine can prevent future migraines. More research is necessary to confirm the effectiveness of hyperbaric oxygen therapy for treating migraines.

Respiratory distress
Patients who are having extreme difficulty breathing – acute respiratory distress syndrome – are commonly given oxygen and there have been limited trials of hyperbaric equipment in such cases. Examples include treatment of the Spanish flu and COVID-19.

Contraindications
The toxicology of the treatment has been reviewed by Ustundag et al. and its risk management is discussed by Christian R. Mortensen, in light of the fact that most hyperbaric facilities are managed by departments of anaesthesiology and some of their patients are critically ill.

An absolute contraindication to hyperbaric oxygen therapy is untreated pneumothorax. The reason is concern that it can progress to tension pneumothorax, especially during the decompression phase of therapy, although treatment on oxygen-based tables may avoid that progression. The COPD patient with a large bleb represents a relative contraindication for similar reasons. Also, the treatment may raise the issue of occupational health and safety (OHS), for chamber inside attendants, who should not be compressed if they are unable to equalise ears and sinuses.

The following are relative contraindications – meaning that special consideration must be made by specialist physicians before HBO treatments begin:
 * Cardiac disease
 * COPD with air trapping – can lead to pneumothorax during treatment.
 * Upper respiratory infections – These conditions can make it difficult for the patient to equalise their ears or sinuses, which can result in what is termed ear or sinus squeeze.
 * High fevers – In most cases the fever should be lowered before HBO treatment begins. Fevers may predispose to convulsions.
 * Emphysema with CO2 retention – This condition can lead to pneumothorax during HBO treatment due to rupture of an emphysematous bulla during decompression. This risk can be evaluated by x-ray.
 * History of thoracic (chest) surgery – This is rarely a problem and usually not considered a contraindication. However, there is concern that air may be trapped in lesions that were created by surgical scarring. These conditions need to be evaluated prior to considering HBO therapy.
 * Malignant disease: Cancers thrive in blood-rich environments but may be suppressed by high oxygen levels. HBO treatment of individuals who have cancer presents a problem, since HBO both increases blood flow via angiogenesis and also raises oxygen levels. Taking an anti-angiogenic supplement may provide a solution. A study by Feldemier, et al. and NIH funded study on Stem Cells by Thom, et al., indicate that HBO is actually beneficial in producing stem/progenitor cells and the malignant process is not accelerated.
 * Middle ear barotrauma is always a consideration in treating both children and adults in a hyperbaric environment because of the necessity to equalise pressure in the ears.

Pregnancy is not a relative contraindication to hyperbaric oxygen treatments, although it may be for underwater diving. In cases where a pregnant woman has carbon monoxide poisoning there is evidence that lower pressure (2.0 ATA) HBOT treatments are not harmful to the fetus, and that the risk involved is outweighed by the greater risk of the untreated effects of CO on the fetus (neurologic abnormalities or death.) In pregnant patients, HBO therapy has been shown to be safe for the fetus when given at appropriate levels and "doses" (durations). In fact, pregnancy lowers the threshold for HBO treatment of carbon monoxide-exposed patients. This is due to the high affinity of fetal hemoglobin for CO.

Therapeutic principles
The therapeutic consequences of HBOT and recompression result from multiple effects.

Clinical pressure (2.0–3.0 Bar)
The increased overall pressure is of therapeutic value in the treatment of decompression sickness and air embolism as it provides a physical means of reducing the volume of inert gas bubbles within the body; Exposure to this increased pressure is maintained for a period long enough to ensure that most of the bubble gas is dissolved back into the tissues, removed by perfusion and eliminated in the lungs.

The improved concentration gradient for inert gas elimination (oxygen window) by using a high partial pressure of oxygen increases the rate of inert gas elimination in the treatment of decompression sickness.

For many other conditions, the therapeutic principle of HBOT lies in its ability to drastically increase partial pressure of oxygen in the tissues of the body. The oxygen partial pressures achievable using HBOT are much higher than those achievable while breathing pure oxygen under normobaric conditions (i.e. at normal atmospheric pressure). This effect is achieved by an increase in the oxygen transport capacity of the blood. At normal atmospheric pressure, oxygen transport is limited by the oxygen binding capacity of hemoglobin in red blood cells and very little oxygen is transported by blood plasma. Because the hemoglobin of the red blood cells is almost saturated with oxygen at atmospheric pressure, this route of transport cannot be exploited any further. Oxygen transport by plasma, however, is significantly increased using HBOT because of the higher solubility of oxygen as pressure increases.

Proangiogenic stem progenitor cell mobilization
A study suggests that exposure to hyperbaric oxygen (HBOT) might also mobilize stem/progenitor cells from the bone marrow by a nitric oxide-dependent mechanism.

Low pressure hyperoxia, stem progenitor cell mobilization and inflammatory cytokine expression
A more recent study suggests that stem cell mobilization, similar to that seen in the Thom study, is also invoked at relative normo-baric pressure with a significantly smaller increase in oxygen concentration. This study also found a significant decrease in the expression of the systemic inflammatory cytokine TNF-α in venous blood. These results suggest that hyperbaria may not be required to invoke the transcriptional responses seen at higher partial pressures of oxygen and that the effect is due solely to oxygen.

Construction
The traditional type of hyperbaric chamber used for therapeutic recompression and HBOT is a rigid shelled pressure vessel. Such chambers can be run at absolute pressures typically about 6 bar, 6 bar or more in special cases. Navies, professional diving organizations, hospitals, and dedicated recompression facilities typically operate these. They range in size from semi-portable, one-patient units to room-sized units that can treat eight or more patients. The larger units may be rated for lower pressures if they are not primarily intended for treatment of diving injuries.

A rigid chamber may consist of:
 * a pressure vessel designed to a code such as ASME Boiler and Pressure Vessel Code
 * viewports to allow the medical personnel to visually monitor the occupants, and can be used for hand signalling as an auxiliary emergency communications method. The major components are the window (transparent acrylic), the window seat (holds the acrylic window), and retaining ring. Interior lighting can be provided by mounting lights outside the viewports. Viewports are a feature specific to PVHOs due to the need to see the people inside and evaluate their health. Other materials have been attempted, but they consistently fail to maintain their seal or have cracks which would progress rapidly to catastrphophic failure. Acrylic is more likely to have small cracks the operators can see and have time to take mitigation steps instead of failing catastrophically. Counterfeit chambers often do not use acrylic windows.
 * one or more human entry hatches – small and circular or wheel-in type hatches for patients on gurneys;
 * the entry lock that allows human entry – a separate chamber with two hatches, one to the outside and one to the main chamber, which can be independently pressurized to allow patients to enter or exit the main chamber while it is still pressurized;
 * a low volume medical or service airlock for medicines, instruments, and food;
 * transparent ports or closed-circuit television that allows technicians and medical staff outside the chamber to monitor the patient inside the chamber;
 * an intercom system allowing two-way communication;
 * an optional carbon dioxide scrubber – consisting of a fan that passes the gas inside the chamber through a soda lime canister;
 * a control panel outside the chamber to open and close valves that control air flow to and from the chamber, and regulate oxygen to hoods or masks;
 * an over-pressure relief valve;
 * a built-in breathing system (BIBS) to supply and exhaust treatment gas;
 * a fire suppression system.

Flexible monoplace chambers are available ranging from collapsible flexible aramid fiber-reinforced chambers which can be disassembled for transport via truck or SUV, with a maximum working pressure of 2 bar above ambient complete with BIBS allowing full oxygen treatment schedules. to portable, air inflated "soft" chambers that can operate at between 0.3 and 0.5 bar above atmospheric pressure with no supplemental oxygen, and longitudinal zipper closure.

Oxygen supply
In the larger multiplace chambers, patients inside the chamber breathe from either "oxygen hoods" – flexible, transparent soft plastic hoods with a seal around the neck similar to a space suit helmet – or tightly fitting oxygen masks, which supply pure oxygen and may be designed to directly exhaust the exhaled gas from the chamber. During treatment patients breathe 100% oxygen most of the time to maximise the effectiveness of their treatment, but have periodic "air breaks" during which they breathe chamber air (21% oxygen) to reduce the risk of oxygen toxicity. The exhaled treatment gas must be removed from the chamber to prevent the buildup of oxygen, which could present a fire risk. Attendants may also breathe oxygen some of the time to reduce their risk of decompression sickness when they leave the chamber. The pressure inside the chamber is increased by opening valves allowing high-pressure air to enter from storage cylinders, which are filled by an air compressor. Chamber air oxygen content is kept between 19% and 23% to control fire risk (US Navy maximum 25%). If the chamber does not have a scrubber system to remove carbon dioxide from the chamber gas, the chamber must be isobarically ventilated to keep the CO2 within acceptable limits.

A soft chamber may be pressurized directly from a compressor. or from storage cylinders.

Smaller "monoplace" chambers can only accommodate the patient, and no medical staff can enter. The chamber may be pressurised with pure oxygen or compressed air. If pure oxygen is used, no oxygen breathing mask or helmet is needed, but the cost of using pure oxygen is much higher than that of using compressed air. If compressed air is used, then an oxygen mask or hood is needed as in a multiplace chamber. Most monoplace chambers can be fitted with a demand breathing system for air breaks. In low pressure soft chambers, treatment schedules may not require air breaks, because the risk of oxygen toxicity is low due to the lower oxygen partial pressures used (usually 1.3 ATA), and short duration of treatment.

For alert, cooperative patients, air breaks provided by mask are more effective than changing the chamber gas because they provide a quicker gas change and a more reliable gas composition both during the break and treatment periods.

Treatments
Initially, HBOT was developed as a treatment for diving disorders involving bubbles of gas in the tissues, such as decompression sickness and gas embolism, It is still considered the definitive treatment for these conditions. The chamber treats decompression sickness and gas embolism by increasing pressure, reducing the size of the gas bubbles and improving the transport of blood to downstream tissues. After elimination of bubbles, the pressure is gradually reduced back to atmospheric levels. Hyperbaric chambers are also used for animals.

As of September 2023, a number of hyperbaric chambers in the US are turning divers with decompression sickness away, and only treating more profitable scheduled cases. The number of hyperbaric medical facilities in the US is estimated at about 1500, of which 67 are treating diving accidents, according to Divers Alert Network. Many facilities only provide hyperbaric treatment for wound care for economic reasons. Emergency hyperbaric services are more expensive to train and staff, and liability is increased.

Protocol
Emergency HBOT for decompression illness follows treatment schedules laid out in treatment tables. Most cases employ a recompression to 2.8 bar absolute, the equivalent of 18 m of water, for 4.5 to 5.5 hours with the casualty breathing pure oxygen, but taking air breaks every 20 minutes to reduce oxygen toxicity. For extremely serious cases resulting from very deep dives, the treatment may require a chamber capable of a maximum pressure of 8 bar, the equivalent of 70 m of water, and the ability to supply heliox as a breathing gas.

U.S. Navy treatment charts are used in Canada and the United States to determine the duration, pressure, and breathing gas of the therapy. The most frequently used tables are Table 5 and Table 6. In the UK the Royal Navy 62 and 67 tables are used.

The Undersea and Hyperbaric Medical Society (UHMS) publishes a report that compiles the latest research findings and contains information regarding the recommended duration and pressure of the longer-term conditions.

Home and out-patient clinic treatment
There are several sizes of portable chambers, which are used for home treatment. These are usually referred to as "mild personal hyperbaric chambers", which is a reference to the lower pressure (compared to hard chambers) of soft-sided chambers. The American Medical Association is opposed to home use or any other use of hyperbaric chambers if it is not "in facilities with appropriately trained staff including physician supervision and prescription and only when the intervention has scientific support or rationale" due demonstrated hazard

In the US, these "mild personal hyperbaric chambers" are categorized by the FDA as CLASS II medical devices and requires a prescription in order to purchase one or take treatments. As with any hyperbaric chamber, the FDA require compliance with ASME and NFPA standards. The most common option (but not approved by FDA) some patients choose is to acquire an oxygen concentrator which typically delivers 85–96% oxygen as the breathing gas.

Oxygen is never fed directly into soft chambers but is rather introduced via a line and mask directly to the patient. FDA approved oxygen concentrators for human consumption in confined areas used for HBOT are regularly monitored for purity (±1%) and flow (10 to 15 liters per minute outflow pressure). An audible alarm will sound if the purity ever drops below 80%. Personal hyperbaric chambers use 120 volt or 220 volt outlets. The FDA warns against the use of oxygen concentrators or oxygen tanks with chambers that does not meet ASME and FDA standards, regardless if the concentrators are FDA approved.

Possible complications and concerns
There are risks associated with HBOT, similar to some diving disorders. Pressure changes can cause a "squeeze" or barotrauma in the tissues surrounding trapped air inside the body, such as the lungs, behind the eardrum, inside paranasal sinuses, or trapped underneath dental fillings. Breathing high-pressure oxygen may cause oxygen toxicity. Temporarily blurred vision can be caused by swelling of the lens, which usually resolves in two to four weeks.

There are reports that cataracts may progress following HBOT' and rarely, may develop de novo, but this may be unrecognized and under reported. The cause is not fully explained, but evidence suggests that lifetime exposure of the lens to high partial pressure oxygen may be a major factor. Oxidative damage to lens proteins is thought to be responsible. This may be an end-stage of the relatively well documented myopic shift detected in most hyperbaric patients after a course of multiple treatments.

Effects of pressure
Patients inside the chamber may notice discomfort inside their ears as a pressure difference develops between their middle ear and the chamber atmosphere. This can be relieved by ear clearing using the Valsalva maneuver or other techniques. Continued increase of pressure without equalizing may cause ear drums to rupture, resulting in severe pain. As the pressure in the chamber increases further, the air may become warm.

To reduce the pressure, a valve is opened to allow air out of the chamber. As the pressure falls, the patient's ears may "squeak" as the pressure inside the ear equalizes with the chamber. The temperature in the chamber will fall. The speed of pressurization and de-pressurization can be adjusted to each patient's needs.

Side effects
Oxygen toxicity is a limitation on both maximum partial pressure of oxygen, and on length of each treatment.

HBOT can accelerate the development of cataracts over multiple repetitive treatments, and can cause temporary relative myopia over the shorter term.

Regulation and legality
The use of hyperbaric chambers for medical and therapeutic procedures is generally regulated. Authorities have warned of potential risks to patients receiving treatment in unlicensed facilities, notably in Israel, Canada, and the United States. In Italy, the use of hyperbaric chambers for therapy was severely restricted to limited medical settings after a serious fire which killed ten patients in 1997.

In some jurisdictions, the use and availability of HBOT is further restricted at the subnational level. In the U.S. state of North Carolina, several cities including Durham, Raleigh and Charlotte have ordered operators of mild hyperbaric oxygen therapy to close to protect public safety due to a risk of fire.

Unlicensed and fraudulent operators have been subject to prosecution. In Australia, Oxymed Australia Pty Ltd and director Malcolm Hooper were ordered to pay AUS $3 million in fines after advertising hyperbaric therapy against the country's Therapeutic Goods Act. In Canada, certain soft-shelled hyperbaric chambers were removed from the market for a potential risk to patients.

Costs
HBOT is recognized by Medicare in the United States as a reimbursable treatment for 14 UHMS "approved" conditions. A 1-hour HBOT session may cost between $300 and higher in private clinics, and over $2,000 in hospitals. U.S. physicians (M.D. or D.O.) may lawfully prescribe HBOT for "off-label" conditions such as stroke, and migraine. Such patients are treated in outpatient clinics. In the United Kingdom most chambers are financed by the National Health Service, although some, such as those run by Multiple Sclerosis Therapy Centres, are non-profit. In Australia, HBOT is not covered by Medicare as a treatment for multiple sclerosis. China and Russia treat more than 80 maladies, conditions and trauma with HBOT.

Personnel

 * Hyperbaric medical practitioner - a specialist in hyperbaric medicine
 * Diving medical practitioner – a specialist in diving medicine
 * Chamber operator – a person competent to operate a hyperbaric chamber
 * Hyperbaric nurse – a nurse responsible for administering hyperbaric oxygen therapy to patients and supervising them throughout the treatment.
 * Diving medical technician – member of a dive team who is trained in advanced first aid.
 * Chamber attendant – a person trained in basic first aid who is medically fit to dive in a chamber, usually a member of a diving team allocated to looking after the diver being treated.

Research
Aspects under research include radiation-induced hemorrhagic cystitis; and inflammatory bowel disease, rejuvenation.

Some research found evidence that HBOT improves local tumor control, mortality, and local tumor recurrence for cancers of the head and neck.

Some research also found evidence of an increase in stem progenitor cells and a decrease in inflammation.

Neurological
Tentative evidence shows a possible benefit in cerebrovascular diseases. Rats subjected to HBOT after some time following the acute phase of experimentally-induced stroke showed reduced inflammation, increased brain-derived neurotrophic factor, and evidence of neurogenesis. Another rat study showed improved neurofunctional recovery as well as neurogenesis following the late-chronic phase of experimentally-induced stroke.

The clinical experience and results so far published has promoted the use of HBOT therapy in patients with cerebrovascular injury and focal cerebrovascular injuries. However, the power of clinical research is limited because of the shortage of randomized controlled trials.

Radiation wounds
A 2010 review of studies of HBOT applied to wounds from radiation therapy reported that, while most studies suggest a beneficial effect, more experimental and clinical research is needed to validate its clinical use.

Hyperbaric air
Junod built a chamber in France in 1834 to treat pulmonary conditions at pressures between 2 and 4 atmospheres absolute.

During the following century "pneumatic centres" were established in Europe and the USA which used hyperbaric air to treat a variety of conditions.

Orval J Cunningham, a professor of anesthesia at the University of Kansas in the early 1900s observed that people with circulatory disorders did better at sea level than at altitude and this formed the basis for his use of hyperbaric air. In 1918, he successfully treated patients with the Spanish flu with hyperbaric air. In 1930 the American Medical Association forced him to stop hyperbaric treatment, since he did not provide acceptable evidence that the treatments were effective.

Hyperbaric oxygen
The English scientist Joseph Priestley discovered oxygen in 1775. Shortly after its discovery, there were reports of toxic effects of hyperbaric oxygen on the central nervous system and lungs, which delayed therapeutic applications until 1937, when Behnke and Shaw first used it in the treatment of decompression sickness.

In 1955 and 1956 Churchill-Davidson, in the UK, used hyperbaric oxygen to enhance the radiosensitivity of tumours, while, at the University of Amsterdam, successfully used it in cardiac surgery.

In 1961 et al. published on the use of hyperbaric oxygen in the treatment of clostridial gas gangrene.

In 1962 Smith and Sharp reported successful treatment of carbon monoxide poisoning with hyperbaric oxygen.

The Undersea Medical Society (now Undersea and Hyperbaric Medical Society) formed a Committee on Hyperbaric Oxygenation which has become recognized as the authority on indications for hyperbaric oxygen treatment.

Incidents
Fires inside a hyperbaric chamber are incredibly dangerous. A review article published in 1997 found 77 human fatalities in 35 different hyperbaric chamber fires that occurred from 1923 to 1996. Further studies indicate while the treatment is often considered safe, the use of hyperbaric medicine comes with risks to the operating personnel for improper use, urging proper machine maintenance and safety procedures for the device's use.


 * 1997: Ten patients and a nurse were killed in Milan, Italy after a fire broke out inside a hyperbaric oxygen chamber.
 * 2009: A grandmother and her four year old grandson perished after a hyperbaric chamber caught fire and exploded in Florida. The boy was receiving treatment in the chamber for cerebral palsy and had traveled from Italy where the treatment is outlawed to undergo the procedure.
 * 2012: A hyperbaric oxygen chamber exploded in Florida, killing a woman and a thoroughbred horse who was receiving treatment. The explosion occurred after the horse kicked out at the chamber, creating sparks which ignited.
 * 2015: A dog was killed in Georgia when the chamber it was receiving treatment in caught fire and exploded. The dog was being treated for arthritis.
 * 2016: A fire killed four people who were receiving treatment inside a hyperbaric chamber at Mintohardjo Navy Hospital in Jakarta, Indonesia. The fire was reportedly caused by an electrical short circuit. After the fire broke out, operators used a sprinkler system and an emergency shut off system to rescue the victims, but live-saving efforts were prevented as the machine became engulfed in flames.
 * 2016: A man in Victoria, Australia died in a hyperbaric chamber while receiving treatment. The practitioners overseeing his care were found responsible for failing to ensure the patient's safety leading to his death. They were later fined AU$716,750.